- /
- Supported exchanges
- / US
- / CMPS.NASDAQ
Compass Pathways Plc (CMPS NASDAQ) stock market data APIs
Compass Pathways Plc Financial Data Overview
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Compass Pathways Plc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Compass Pathways Plc data using free add-ons & libraries
Get Compass Pathways Plc Fundamental Data
Compass Pathways Plc Fundamental data includes:
- Net Revenue:
- EBITDA: -154 376 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: -0.3955
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Compass Pathways Plc News
New
Cathie Wood Pours $24 Million to This AI Software Stock
This article first appeared on GuruFocus. Cathie Wood's ARK Invest added to Figma (NYSE:FIG) and trimmed DraftKings (NASDAQ:DKNG) on Feb. 19, as part of a broader portfolio reshuffle. ARK funds boug...
Analysts Bullish on COMPASS Pathways plc (CMPS) Following Psychedelics Symposium and Model Updates
COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds.Analysts Bullish on COMPASS Pathways plc (CMPS) Following Psychedelics Symposium and Model ...
Why Did Compass Pathways Stock Rocket Higher Today?
It's been a long road for Compass Pathways(NASDAQ: CMPS) to prove that its treatment using psilocybin therapy for treatment-resistant depression (TRD) can be successful. It was back in 2018 when the c...
Why Did Compass Pathways Stock Rocket Higher Today?
Key Points Phase 3 clinical trial data has been a success. COMP360 is the first traditional psychedelic to consistently deliver a highly statistically significant outcome. Results included maintaini...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.